Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suramin with Docetaxel and Carboplatin in Chemo-Naive NSCLC
NCT01038752Phase 2Terminated
- Sponsor
- Optimum Therapeutics
- Start
- Aug 2010
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of suramin in non-small cell lung cancer (NSCLC), sponsored by Optimum Therapeutics. Started Aug 2010; status: terminated.
02
Drugs
suramin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01038752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01038752.